PAPER Rapoport SI, Nelson PT

Biomarkers and evolution in Alzheimer disease.

Prog Neurobiol. 2011 Dec;95(4):510-3. PubMed: 21801803

PAPER Hara H, Mouri A, Yonemitsu Y, Nabeshima T, Tabira T

Mucosal immunotherapy in an Alzheimer mouse model by recombinant Sendai virus vector carrying Aβ1-43/IL-10 cDNA.

Vaccine. 2011 Oct 6;29(43):7474-82. PubMed: 21803105

PAPER Royall DR, Palmer RF, Petrovitch H, Ross GW, Masaki K, White LR

Modeling regional vulnerability to Alzheimer pathology.

Neurobiol Aging. 2011 Jul 29; PubMed: 21803455

PAPER Molinuevo JL, Hernández B,

[Profile of the informal carer associated with the clinical management of the Alzheimer's disease patient refractory to symptomatic treatment of the disease].

Neurologia. 2011 Nov;26(9):518-27. PubMed: 21803459

PAPER Shimazawa R, Ikeda M

Delays in neurological drug development in Japan.

Intern Med. 2011;50(15):1565-8. PubMed: 21804282

PAPER Koedam EL, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YA, Fox N, Barkhof F, Wattjes MP

Visual assessment of posterior atrophy development of a MRI rating scale.

Eur Radiol. 2011 Dec;21(12):2618-25. PubMed: 21805370

PAPER Paige JS, Wu KY, Jaffrey SR

RNA mimics of green fluorescent protein.

Science. 2011 Jul 29;333(6042):642-6. PubMed: 21798953

William Rodman Shankle on Paris: More Trial News, Mixed at Best

COMMENT I'd like to expand on Bonetta's coverage of our work. The implication of our presentation on IVIG is that IVIG therapy may delay progression of more than just AD. The most parsimonious explanation for a disease-modifying effect of IVIG in both A

bhakti patel

cuttack, India

Rui Hua

China

Paris: More Trial News, Mixed at Best

CONFERENCE COVERAGE 2011-08-02 Conference Coverage Updated 03 August 2011. With the buzz surrounding amyloid-targeting therapies, it is easy to lose sight of the fact that other treatments are being tested as well. Presentations at the 11th annual Alzheimer’s Association International

Hedgehog Protocol Turns Supersonic in Faster Route to Motor Neurons

RESEARCH NEWS 2011-08-02 Research News It takes sonic hedgehog, retinoic acid, and more than a month to turn stem cells into a few motor neurons for study or, eventually, transplantation. For researchers keen to understand amyotrophic lateral sclerosis and other motor neuron cond

Sam Gandy on LRAD3, a novel low-density lipoprotein receptor family member that modulates amyloid precursor protein trafficking.

COMMENT This work looks very solid and very interesting. We seem to have moved from the “secretase generation” to the “sortase generation,” what with LRP, vps35, SORL1, and SORCS1 all playing key roles in sorting APP and its C-terminal fragments in and out of Aβ-

G. William Rebeck on LRAD3, a novel low-density lipoprotein receptor family member that modulates amyloid precursor protein trafficking.

COMMENT This work from Dudley Strickland's lab describes a new protein related to the LDL receptor family, termed LRAD3. This protein shares structural similarities to other members of the family, including domains for the internalization and sorting of (as

PAPER Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK

LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation.

Cell. 1995 Jul 28;82(2):331-40. PubMed: 7543026